Skip to main content
. 2024 Feb 5;2024(2):CD015219. doi: 10.1002/14651858.CD015219.pub2

Sirijatuphat 2022.

Study characteristics
Methods Multicentre, open‐label RCT
Participants People with mild cases of COVID‐19 without pneumonia.
Interventions Favipiravir, standard of care
Outcomes Favipiravir's effects on viral clearance, clinical improvement, risk of COVID‐19 pneumonia development, adverse events
Notes